Efficacy of tolvaptan for chronic heart failure
Study protocol for a systematic review of randomized controlled trial
Wei-qin Gao, MM, Xiang-dong Meng, MM*, Ze Sun, MM

Abstract

Background: The protocol of this study will be proposed for systematic evaluation of the efficacy and safety of tolvaptan in the treatment of chronic heart failure (CHF).

Methods: We will retrieve the following electronic databases for randomized controlled trials assessing the efficacy of tolvaptan in patients with CHF: PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, Scopus, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, VIP Information, and Wanfang Data. Each database will be retrieved from inception to February 1, 2019 without any limitations. The entire process of study selection, data extraction, and methodological quality evaluation will be conducted by 2 independent authors.

Results: The protocol of this proposed study will compare the efficacy and safety of tolvaptan in the treatment of patients with CHF. The outcomes will include all-cause mortality, change in body weight, urine output, change in serum sodium; and incidence of all adverse events.

Conclusion: The findings of this proposed study will summarize the current evidence of tolvaptan for CHF.

Ethics and dissemination: All data used in this systematic review will be collected from the previous published trials. Thus, no research ethics approval is needed for this study. The findings of this study will be published at a peer-reviewed journal.

PROSPERO registration number: PROSPERO CRD42019120818.

Abbreviations: CENTRAL = Cochrane Central Register of Controlled Trials, CHF = chronic heart failure, CIs = confidence intervals, RCTs = randomized controlled trials.

Keywords: chronic heart failure, efficacy, randomized controlled trial, safety, tolvaptan

1. Introduction

Chronic heart failure (CHF) is one of the most serious cardiovascular diseases all over the world.[1–4] It often causes a series of cardiac dysfunctions, such as ejection dysfunction, decreased cardiac output, and increased intracardiac pressure function.[5–7] Most importantly, this condition also results in high mortality, with about 50% within 5 years.[8] Epidemiological studies have reported that its prevalence is about 1 to 2% among general population.[9–10] The huge cost of CHF treatment also brings the greatest burden for both families and society.[11–13]

Several previous trials have reported that tolvaptan can be used to treat heart failure effectively.[14–22] Although one systematic review has assessed efficacy and safety of tolvaptan for the treatment of acute heart failure,[23] no systematic review and meta-analysis has been conducted to specifically explore the efficacy and safety of tolvaptan for CHF based on many published clinical trials of CHF.[24–28] Therefore, in this proposed protocol of systematic review, we will specifically investigate the efficacy and safety of tolvaptan for the treatment of CHF.

2. Methods

2.1. Inclusion criteria for study selection

2.1.1. Study types. This proposed study will include randomized controlled trials (RCTs) that have assessed all types of tolvaptan for the treatment of patients with CHF. No restrictions of the location, time, and language of published papers will be applied. However, we will not consider non-clinical studies, case studies, non-RCTs, and quasi-RCTs.

2.1.2. Participants. All participants must be clinically diagnosed as CHF, and will be considered without any limitations of race, gender, and age.

2.1.3. Interventions. The experimental group must have been treated with tolvaptan alone. The control group must have been treated with other therapies, but not any types of tolvaptan.

2.1.4. Outcomes. The primary outcome includes all-cause mortality. The secondary outcomes consist of change in body weight, urine output, change in serum sodium; and incidence of all adverse events.

X-dM and W-qG contributed equally to this study.

This study was supported by the Heilongjiang Provincial Health Department Scientific Research Project (2011–2014).

The authors have no conflicts of interest to disclose.

First Ward of Cardiology Department, First Affiliated Hospital of Jiamusi University, Jiamusi, China.

* Correspondence: Xiang-dong Meng, First Ward of Cardiology Department, First Affiliated Hospital of Jiamusi University, No. 348 Dexiang Street, Jiamusi, 154002, China (e-mail: Xiangdongmeng2000@outlook.com).

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Medicine (2019) 98:7(e14540)
Received: 23 January 2019 / Accepted: 24 January 2019
https://dx.doi.org/10.1097/MD.0000000000014540
2.3.1. Study selection. Two independent authors will initially scan titles and abstracts of all potential studies. Then, full texts will be further read if there will be insufficient information to judge the study according to the inclusion criteria. Disagreements will be solved by discussion with other authors. The flowchart of study selection is demonstrated in Figure 1.

2.3.2. Data extraction and management. Two independent authors will conduct data extraction according to the predefined standard data extraction form. The divergences will be resolved by consulting other authors. The form comprises of the following information: title, 1st author, year of publication, diagnosed criteria, inclusion and exclusion criteria, sample size, details of randomization, allocation, and blinding, intervention details, and outcomes. Any insufficient or missing data will be inquired by contacting the primary authors through email.

2.3.3. Methodological quality evaluation. We will evaluate the methodological quality in each study by using Cochrane Risk of Bias Tool. Two independent authors will evaluate methodological quality for each study. Any divisions will be settled down by discussion with other authors.

2.4. Statistical analysis

We will use ReMan 5.3 software to pool and analyze the data. Continuous outcome data will be synthesized and presented as mean difference or standardized mean difference with 95% confidence intervals (CIs). Dichotomous outcome data will be synthesized and shown as risk ratio with 95% CIs.

Heterogeneity among included studies will be identified by $I^2$ test. The $I^2 < 50\%$ is set as having reasonable heterogeneity, and a fixed-effect model will be used to pool and analyze the data. The $I^2 > 50\%$ is considered as having significant heterogeneity, and a random-effect model will be utilized to pool and analyze the data. Then, subgroup analysis will be conducted to detect the possible reasons that may account for high heterogeneity. It will be carried out according to the different study characteristics, types of treatments, and outcome measurements. If it does not work, the pooled data and meta-analysis will not be performed. Instead, a narrative summary will be reported.

Additionally, sensitivity analysis will be carried out to identify the robustness of pooled results by removing low quality trials. Moreover, unit of analysis will be considered to conduct if cross-over studies included, and only 1st period of study data will be pooled and analyzed. Finally, reporting biases will also be performed by using funnel plot$^{[29]}$ and Egger’s regression,$^{[30]}$ if more than 10 studies are included.

3. Discussion

The CHF is a very server cardiovascular disease, and often result in very high mortality. Tolvaptan is reported to treat heart failure effectively, especially for acute heart failure. However, no systematic review has addressed its efficacy and safety for the treatment of patients with CHF, although lots of high quality clinical trials have been published.$^{[24–28]}$ Thus, this study will firstly and systematically explore the efficacy and safety of tolvaptan for CHF. It will provide the first rigorous summary evidence of tolvaptan for CHF across all published RCTs.

The data pooled results will provide a better understanding of efficacy and safety of tolvaptan for patients with CHF. Its findings will inform our understanding of the value of tolvaptan in treating CHF outcomes. Additionally, it may also provide helpful evidence for clinical practice and future studies.

Acknowledgments

This study is supported by the Heilongjiang Provincial Health Department Scientific Research Project (2011-354). The funder had no role in the design, execution, or writing of the study.
Author contributions
Conceptualization: Wei-qin Gao, Xiang-dong Meng, Ze Sun. Data curation: Wei-qin Gao, Xiang-dong Meng, Ze Sun. Formal analysis: Wei-qin Gao, Ze Sun. Funding acquisition: Wei-qin Gao, Xiang-dong Meng. Investigation: Xiang-dong Meng. Methodology: Wei-qin Gao, Xiang-dong Meng, Ze Sun. Project administration: Xiang-dong Meng. Resources: Wei-qin Gao, Xiang-dong Meng, Ze Sun. Software: Wei-qin Gao, Ze Sun. Supervision: Xiang-dong Meng. Validation: Wei-qin Gao, Xiang-dong Meng, Ze Sun. Visualization: Wei-qin Gao, Xiang-dong Meng, Ze Sun. Writing – original draft: Wei-qin Gao, Xiang-dong Meng. Writing – review & editing: Wei-qin Gao, Xiang-dong Meng, Ze Sun.

References
[1] Triposkiadis FK, Skoularigis J. Prevalence and importance of comorbidities in patients with heart failure. Curr Heart Fail Rep 2012;9:354–62.
[2] Conde-Martel A, Hernández-Meneses M. Prevalence and prognostic meaning of comorbidity in heart failure. Rev Clin Esp 2016;216:222–8.
[3] van Riet EE, Hoes AW, Wagenaar KP, et al. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail 2016;18:242–52.
[4] Denfeld QE, Winters-Stone K, Mudd JO, et al. The prevalence of frailty in heart failure: a systematic review and meta-analysis. Int J Cardiol 2017;236:283–9.
[5] Chaudhry SP, Stewart GC. Advanced heart failure: prevalence, natural history, and prognosis. Heart Fail Clin 2016;12:323–33.
[6] Cainzos-Achirica M, Rebordosa C, Vela E, et al. Challenges of evaluating chronic heart failure and acute heart failure events in research studies using large health care databases. Am Heart J 2018;202:76–83.
[7] Zhang D, Tu H, Wadman MC, et al. Substrates and potential therapeutic strategies of ventricular arrhythmias in heart failure. Eur J Pharmacol 2018;833:349–56.
[8] Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation 2017;135:e146–603.
[9] Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007;93:1137–46.
[10] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891–975.
[11] Fergenbaum J, Bermingham S, Krahn M, et al. Care in the home for the management of chronic heart failure: systematic review and cost-effectiveness analysis. J Cardiovase Nurs 2015;30(4 Suppl 1):S44–51.
[12] Nandi D, Rossano JW. Epidemiology and cost of heart failure in children. Cardiol Young 2015;25:1460–8.
[13] Rice H, Say R, Betihavas V. The effect of nurse-led education on hospitalisation, readmission, quality of life and cost in adults with heart failure. A systematic review. Patient Educ Couns 2018;101:363–74.
[14] Gheorghiade M, Gattis WA, O’Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004;291:1963–71.
[15] Felker GM, Mentz RJ, Cole RT, et al. Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure. J Am Coll Cardiol 2017;69:1399–406.
[16] Shannagam E, Doss CR, George M, et al. Effect of tolvaptan on acute heart failure with hyponatremia—a randomized, double blind, controlled clinical trial. Indian Heart J 2016;68(Suppl 1):S15–21.
[17] Matsuyoshi A, Suzuki M, Torii S, et al. Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction. J Card Fail 2016;22:423–32.
[18] Kimura K, Momose T, Hasegawa T, et al. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure. J Cardiol 2016;67:399–405.
[19] Suzuki S, Yoshihisa A, Yamaki T, et al. Long-term effects and prognosis in acute heart failure treated with tolvaptan: the AVCMA trial. Biomed Res Int 2014;2014:704289.
[20] Suzuki S, Yoshihisa A, Yamaki T, et al. Acute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitide. J Clin Pharmacol 2013;53:1277–85.
[21] Van Wart SA, Shoaib SE, Mallikarjuna S, et al. Population pharmacokinetics of tolvaptan in healthy subjects and patients with hyponatremia secondary to congestive heart failure or hepatic cirrhosis. Biopharm Drug Dispos 2013;34:336–47.
[22] Udelson JE, Bilsker M, Hauptman PJ, et al. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction. J Card Fail 2011;17:973–81.
[23] Wang C, Xiong B, Cai L. Effects of tolvaptan in patients with acute heart failure: a systematic review and meta-analysis. BMC Cardiovasc Disord 2017;17:164.
[24] Sağ S, Aydin Kaderli A, Yıldız A, et al. Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey. Turk Kardiyol Dern Ars 2017;45:415–25.
[25] Katsumata M, Hirawa N, Sumida K, et al. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure. Clin Exp Nephrol 2017;21:858–65.
[26] Kadota M, Isé T, Yagi S, et al. Response prediction and influence of tolvaptan in chronic heart failure patients considering the interaction of the renin-angiotensin-aldosterone system and arginine vasopressin. Int Heart J 2016;57:461–5.
[27] Watanabe K, Dohi K, Sagimoto T, et al. Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure. J Cardiol 2012;60:462–69.
[28] Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003;107:2690–6.
[29] Sutton AJ, Duval SJ, Tweedie RL, et al. Empirical assessment of effect of publication bias on meta-analyses. BMJ 2000;320:1574–7.
[30] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.